Neurocrine Biosciences, Inc. (Nasdaq: NBIX) has appointed Dr. Sanjay Keswani as Chief Medical Officer (CMO), marking a significant leadership transition as the company accelerates its clinical development strategy. Dr. Keswani succeeds Dr. Eiry W. Roberts, who transitions to a strategic advisory role after a transformative seven-year tenure.
Dr. Keswani, a physician-scientist with over two decades in the pharmaceutical industry, will spearhead Neurocrine’s clinical development and medical affairs. He brings experience from leading roles at ImmunoBrain, Roche, and Bristol-Myers Squibb. His expertise spans neuroimmune therapies, neuroscience, rare diseases, and immunology. A Johns Hopkins-trained neurologist, Dr. Keswani is also a Fellow of the Royal College of Physicians, UK.
Dr. Kyle W. Gano, CEO of Neurocrine, noted, “Sanjay’s leadership will expand our capabilities into new therapeutic modalities, supporting our continued R&D excellence.”
Dr. Roberts’ legacy includes the development of key treatments such as INGREZZA® and CRENESSITY™, establishing Neurocrine’s strong clinical foundation.